Ubs Group Ag Rhythm Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 272,108 shares of RYTM stock, worth $17.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

272,108

Previous 254,264 7.02%

Holding current value

$17.8 Million

Previous $14.2 Million 1.41%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$48.56 - $61.02 $866,504 - $1.09 Million	17,844 Added 7.02%	272,108 $14.4 Million
Q4 2024 Feb 14, 2025	BUY	$46.91 - $67.33 $8.33 Million - $12 Million	177,630 Added 231.79%	254,264 $14.2 Million
Q3 2024 Nov 14, 2024	BUY	$40.81 - $55.0 $436,340 - $588,060	10,692 Added 16.21%	76,634 $4.01 Million
Q2 2024 Aug 13, 2024	SELL	$35.41 - $44.37 $3.74 Million - $4.69 Million	-105,623 Reduced 61.56%	65,942 $2.71 Million
Q1 2024 May 13, 2024	BUY	$39.12 - $52.44 $3.35 Million - $4.49 Million	85,610 Added 99.6%	171,565 $7.43 Million
Q4 2023 Feb 09, 2024	BUY	$21.39 - $49.64 $1.27 Million - $2.94 Million	59,304 Added 222.52%	85,955 $3.95 Million
Q3 2023 Nov 09, 2023	SELL	$15.81 - $27.8 $967,540 - $1.7 Million	-61,198 Reduced 69.66%	26,651 $610,000
Q2 2023 Aug 11, 2023	BUY	$16.32 - $21.15 $61,559 - $79,777	3,772 Added 4.49%	87,849 $1.45 Million
Q1 2023 May 12, 2023	SELL	$16.88 - $34.24 $1.81 Million - $3.67 Million	-107,188 Reduced 56.04%	84,077 $1.5 Million
Q4 2022 Feb 08, 2023	BUY	$22.21 - $30.25 $3.97 Million - $5.4 Million	178,630 Added 1413.77%	191,265 $5.57 Million
Q3 2022 Nov 10, 2022	BUY	$4.3 - $30.85 $22,050 - $158,198	5,128 Added 68.31%	12,635 $309,000
Q2 2022 Aug 10, 2022	BUY	$3.12 - $12.25 $21,861 - $85,835	7,007 Added 1401.4%	7,507 $31,000
Q1 2022 May 16, 2022	SELL	$6.13 - $12.24 $631,880 - $1.26 Million	-103,080 Reduced 99.52%	500 $6,000
Q4 2021 Feb 14, 2022	BUY	$8.62 - $13.9 $194,898 - $314,279	22,610 Added 27.92%	103,580 $1.03 Million
Q3 2021 Nov 15, 2021	BUY	$11.68 - $20.72 $9,939 - $17,632	851 Added 1.06%	80,970 $1.06 Million
Q2 2021 Aug 13, 2021	SELL	$18.52 - $22.55 $865,458 - $1.05 Million	-46,731 Reduced 36.84%	80,119 $1.57 Million
Q1 2021 May 12, 2021	BUY	$20.25 - $39.49 $520,404 - $1.01 Million	25,699 Added 25.41%	126,850 $2.7 Million
Q4 2020 Feb 11, 2021	BUY	$21.17 - $32.61 $1.25 Million - $1.92 Million	58,894 Added 139.37%	101,151 $3.01 Million
Q3 2020 Nov 12, 2020	BUY	$18.13 - $30.61 $761,659 - $1.29 Million	42,011 Added 17077.64%	42,257 $916,000
Q2 2020 Jul 31, 2020	SELL	$14.41 - $25.35 $80,393 - $141,427	-5,579 Reduced 95.78%	246 $5,000
Q1 2020 May 01, 2020	BUY	$13.16 - $22.9 $53,745 - $93,523	4,084 Added 234.58%	5,825 $89,000
Q4 2019 Feb 14, 2020	SELL	$19.53 - $25.5 $649,001 - $847,390	-33,231 Reduced 95.02%	1,741 $40,000
Q3 2019 Nov 14, 2019	BUY	$18.62 - $24.51 $637,101 - $838,634	34,216 Added 4525.93%	34,972 $755,000
Q2 2019 Aug 14, 2019	BUY	$21.11 - $28.48 $12,032 - $16,233	570 Added 306.45%	756 $17,000
Q1 2019 May 14, 2019	SELL	$24.76 - $31.66 $252,007 - $322,235	-10,178 Reduced 98.21%	186 $5,000
Q4 2018 Feb 14, 2019	BUY	$24.11 - $31.34 $130,386 - $169,486	5,408 Added 109.12%	10,364 $279,000
Q3 2018 Nov 14, 2018	BUY	$26.99 - $35.85 $64,479 - $85,645	2,389 Added 93.07%	4,956 $145,000
Q2 2018 Aug 14, 2018	BUY	$17.02 - $35.2 $27,640 - $57,164	1,624 Added 172.22%	2,567 $80,000
Q1 2018 May 15, 2018	SELL	$19.9 - $32.25 $157,389 - $255,065	-7,909 Reduced 89.35%	943 $19,000
Q4 2017 Feb 14, 2018	BUY	$22.0 - $30.51 $194,744 - $270,074	8,852	8,852 $257,000

Others Institutions Holding RYTM

# of Institutions

245

Shares Held

62.9M

Call Options Held

403K

Put Options Held

62.8K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.65B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account